Pro zobrazení tohoto obsahu je třeba být přihlášen.
Categories for Uncategorized
SAFETY AND EFFICACY OF RUXOLITINIB (RUX) IN PATIENTS WITH MYELOFIBROSIS (MF) AND ANEMIA (HB < 10 G/DL): RESULTS AT WEEK (WK) 24 OF THE REALISE TRIAL
26 ledna, 2021 8:54 pmAuthor(s): Francisco Cervantes, Heinz Gisslinger, Atanas Radinoff, et. al. EHA Library. Jun 15, 2019; 267082; PS1465 Session topic: 16....
SURVIVAL OUTCOMES IN MYELOFIBROSIS PATIENTS TREATED WITH RUXOLITINIB: A POPULATION- -BASED COHORT STUDY IN SWEDEN AND NORWAY
26 ledna, 2021 8:53 pmAuthor(s): Frida Schain, Emese Vago, Jianming He, et. al. EHA Library. Jun 15, 2019; 267080; PS1463 Session topic: 16....
EARLY SPLEEN RESPONSE IS A GOOD PROGNOSTIC FACTOR OF RUXOLINIB OUTCOME IN PATIENTS WITH MYELOFIBROSIS
26 ledna, 2021 8:53 pmAuthor(s): Elza Lomaia, Nadiya Siordiya, Georgy Dimov, et. al. EHA Library. May 16, 2019; 268118; PB2207 Session topic: 16....
Novinky z kongresu: Myeloproliferatívna neoplázia
26 ledna, 2021 8:53 pmPo šiestich rokoch sa kongres európskej hematologickej asociácie vrátil do hlavného mesta Holandska. Program kongresu zahŕňal všetky podkategórie hematológie a choroby...
SAFETY AND CLINICAL ACTIVITY OF AMV564, A CD33/CD3 T-CELL ENGAGER, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA (AML): UPDATED RESULTS FROM THE PHASE 1 FIRST-IN-HUMAN TRIAL
26 ledna, 2021 8:53 pmAuthor(s): P. Westervelt, G. J. Roboz, J. E. Cortes, J. K. Altman, V. G. Oehler, et al. EHA Library. Westervelt...
THE FIRST-IN-CLASS ANTI-CD47 ANTIBODY HU5F9-G4 WITH RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS
26 ledna, 2021 8:53 pmAuthor(s): R. Advani, N. Bartlett, S. Smith, M. Roschewski, L. Popplewell, et al. EHA Library. Roschewski M. Jun 15, 2019;...
PEGCRISANTASPASE AND VENETOCLAX COMBINATION IS HIGHLY EFFECTIVE AGAINST ACUTE MYELOID LEUKEMIA (AML), MECHANISTICALLY DRIVEN SYNERGISM BETWEEN GLUTAMINE DEPLETION AND BCL-2 INHIBITION
26 ledna, 2021 8:53 pmAuthor(s): A. Emadi1, R. Gartenhaus, B. Bhandary, H. Kaizer, E. Chang, et al. EHA Library. Emadi A. Jun 15, 2019;...
THE SINGLE-CELL ATLAS OF DRIVER MUTATIONS IN AML
26 ledna, 2021 8:53 pmAuhor(s): K. Morita, F. Wang, K. Jahn, Y. Yan, R. Durruthy-Durruthy, et al. EHA Library. Morita K. Jun 15, 2019;...
DECIPHERING THE ROLE OF RUNX1 ISOFORMS IN THE DEVELOPMENT OF TRANSIENT ABNORMAL MYELOPOIESIS
26 ledna, 2021 8:53 pmAuthor(s): S. Gialesaki, M. Labuhn, D. Brauer-Hartmann, S. Matzk, F.-J. Struwe, et al. EHA Library. Gialesaki S. Jun 14, 2019;267347;...
Co je nového v léčbě AML?
26 ledna, 2021 8:53 pmVe dnech 13.–16. června 2019 se v Amsterdamu konal 24. kongres Evropské hematologické společnosti, který přinesl komplexní přehled novinek z oblasti onkologické a neonkologické...